NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Cell Therapeutics, Inc. (BIT: CTIC)

 
CTIC Technical Analysis
4
As on 1st Nov 2017 CTIC Share Price closed @ 2.67 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.22 & Strong Sell for SHORT-TERM with Stoploss of 2.75 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

CTIC Share Price

Open 2.75 Change Price %
High 2.75 1 Day -0.01 -0.37
Low 2.67 1 Week 0.00 0.00
Close 2.67 1 Month -0.08 -2.91
Volume 74249 1 Year 2.31 641.67
52 Week High 5.68 | 52 Week Low 0.35
 
BIT Italy Most Active Stocks
RN 0.04 0.00%
PMI 0.36 0.00%
TIT 0.75 1.35%
ISP 2.89 0.00%
F 6.94 -2.12%
TIS 0.04 0.00%
SPM 3.80 5.26%
ENEL 5.39 1.32%
TITR 0.62 1.64%
CRG 0.21 0.00%
 
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
AE 0.50 8.70%
AE 0.50 8.70%
DIS 0.28 7.69%
DIS 0.28 7.69%
DIS 0.28 7.69%
DIS 0.28 7.69%
 
BIT Italy Top Losers Stocks
ME 0.09 -10.00%
ME 0.09 -10.00%
FTL 3.65 -7.36%
TBS 1.64 -6.82%
STEF 0.19 -5.00%
POPR 0.59 -4.84%
BIM 0.65 -4.41%
BIM 0.65 -4.41%
ZUCR 0.24 -4.00%
S24 1.70 -3.95%
 
 
CTIC
Daily Charts
CTIC
Intraday Charts
Whats New @
Bazaartrend
CTIC
Free Analysis
 
CTIC Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE2.74
RESISTANCE2.71
SUPPORT2.63
SUPPORT2.60
SUPPORT0.00
SUPPORT0.00
 
CTIC Target for Month November
4th UP TARGET3.91
3rd UP TARGET3.52
2nd UP TARGET3.28
1st UP TARGET3.04
1st DOWN TARGET2.36
2nd DOWN TARGET2.12
3rd DOWN TARGET1.88
4th DOWN TARGET1.49
 
CTIC Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
CTIC Target for Year 2020
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
CTIC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
CTIC Address
CTIC
3101 Western Avenue
Suite 600
Seattle, WA 98121
United States
Phone: 206-282-7100
Fax: 206-284-6206
 
CTIC Latest News
 
Your Comments and Response on Cell Therapeutics, Inc.
 
CTIC Business Profile
Cell Therapeutics, Inc., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral inhibitor of Janus Kinase 2 and FMS-like tyrosine kinase, which is in phase III clinical trials for the treatment of myelofibrosis; and is in phase II clinical trial for treatment of relapsed acute myeloid leukemia. In addition, it is developing Tosedostat, an oral aminopeptidase inhibitor that is in phase II clinical trials for the treatment of acute myeloid leukemia; and is in phase II clinical trials for the treatment of acute myeloid leukemia/myelodysplastic syndrome. Further, the company is developing Opaxio, a chemotherapeutic agent that is in phase III clinical trials for the treatment of ovarian cancer; in phase II clinical trials for the treatment of malignant brain cancer; and is in phase II clinical trials for the treatment of head and neck cancer. Additionally, it is developing Brostallicin, which is in phase II clinical trials for the treatment of triple-negative breast cancer. The company has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat in North, Central, and South America, or the licensed territory; and a development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA to develop and commercialize Pacritinib worldwide. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
 
2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service